{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 8.1.7 Planned Sensitivity and Subgroup Analyses', 'Delete: last paragraph', 'In', 'the DLL3high and randomized sets, CRAC assessed ORR will be compared between the', '2 arms, using a chi-square test for each subgroup. Odds ratios will be presented.', 'Section 8.1.8 Pharmacokinetic and Exposure-Response Analyses', 'First paragraph previously read:', 'Plasma concentrations of rovalpituzumab tesirine ADC as well as the incidence and', 'timing of ATA formation will be tabulated and summary statistics will be computed.', 'Plasma concentration and ATA data from this study may be combined with data from', 'other studies and analyzed using population pharmacokinetic methodologies.', 'Has been changed to read:', 'Serum concentrations of rovalpituzumab tesirine ADC as well as the incidence and timing', 'of ATA formation will be tabulated and summary statistics will be computed. Serum', 'concentration and ATA data from this study may be combined with data from other', 'studies and analyzed using population pharmacokinetic methodologies.', 'Section 8.3 Type I Error Adjustment Procedure for Multiple Testing', 'Previously read:', 'To meet global regulatory requirements, a multiple testing strategy will be implemented to', 'control the family-wise type I error (alpha) for comparisons of rovalpituzumab tesirine', 'arm versus placebo arm with respect to progression-free survival (PFS) per CRAC,', 'overall survival (OS), ORR per CRAC, and physical functioning scale score (EORTC', 'QLQ-C30).', 'The following null hypotheses are considered for subjects with DLL3 high.', 'H1: Rovalpituzumab tesirine arm is not superior to placebo arm in both PFS and OS.', '193']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'H2: Rovalpituzumab tesirine arm is not superior to placebo arm in ORR per CRAC.', 'H3: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning', 'scale score (EORTC QLQ-C30).', 'The null hypotheses will be tested in a fixed sequence of {H1, H2, H3) in order. To', 'maintain the family-wise type I error for the study, the null hypothesis H1 will be first', 'tested with an alpha-split approach. The hypothesis for PFS will be tested at a one-sided', '0.25% level of significance and the hypothesis for OS at a one-sided 2.25% level of', 'significance. If either PFS or os endpoint reaches statistical significance, the study is', 'considered positive. No further tests will be performed if H1 is not rejected. Each', 'hypothesis of H2 and H3 will be tested in order specified above if H1 is rejected and the', 'preceding hypothesis shows statistically significant results at the 1-sided 2.5% level of', 'significance. Otherwise testing in the hierarchical sequence will stop.', 'The secondary efficacy endpoints, e.g., PFS per investigator assessment, ORR per', 'investigator assessment, CBR per CRAC, CBR per investigator assessment, DOR per', 'CRAC, DOR per investigator assessment, and PRO evaluations in the DLL3 high set will be', 'tested at a one-sided 2.5% level of significance. Similarly, OS, PFS per CRAC, and ORR', 'per CRAC in the randomized set will be tested at a one-sided 2.5% level.', 'Has been changed to read:', 'To meet global regulatory requirements, a multiple testing strategy will be implemented to', 'control the family-wise type I error (alpha) to one-sided 0.025 level for comparisons of', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival', '(PFS) per CRAC in DLL3 high set, overall survival (OS) in DLL3 high set, PFS per CRAC in', 'randomized set, OS in randomized set, and physical functioning scale score (EORTO', 'QLQ-C30) in randomized set.', 'The following null hypotheses are considered:', 'Two hypotheses in H01 are Ho1a and Holb.', '194']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Ho1a: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'DLL3 high set.', 'Holb: Rovalpituzumab tesirine arm is not superior to placebo arm in OS in DLL3 high', 'set.', 'H02: Rovalpituzumab tesirine arm is not superior to placebo arm in OS in randomized set.', 'H03: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'randomized set.', 'H04: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning', 'scale score (EORTC QLQ-C30) in randomized set.', 'The null hypotheses will be tested in a fixed sequence of {Hola, Hoib, H02, H03, and H04} in', 'order. To maintain the family-wise type I error for the study, the null hypotheses in Hoi', '(Ho1a and H01b) will be first tested with an alpha-split approach. The one-sided alpha of', '0.25% and 2.25% will be assigned for PFS and OS hypothesis in H01, respectively. Out of', 'one-sided alpha of 2.25% allocated to os hypothesis (Ho1b), the one-sided alpha of 10-6', 'will be spent for the early look at the os data for futility analysis. If the hypothesis for', 'PFS in H01 (Ho1a) is rejected the one-sided alpha of 0.25% will be recycled to the OS', 'hypothesis in H01 (Hoib). Hence, the hypothesis for OS in H01 (Hoib) will be tested either', 'at a one-sided 2.4999% or one-sided 2.2499% level of significance depending on the PFS', 'hypothesis in H01a is rejected or not.', 'If either PFS or OS endpoint reaches statistical significance, the study is considered', 'positive. No further tests will be performed if the OS endpoint in DLL3 high population', '(H01b) does not reach statistical significance.', 'The hypothesis in H02 will be tested if the hypothesis in Holb is rejected. If the hypothesis', 'in H02 is rejected, then, either (i) H03 and H04 will be tested sequentially if the PFS', 'endpoint in DLL3 high subjects (Ho1a) is also rejected or (ii) only H04 will be tested if the', 'PFS endpoint in DLL3 high subjects (H01a) is not rejected.', '195']\n\n###\n\n", "completion": "END"}